Clinical and immunologic effects of Staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII

John Freedman, John W. Semple, Jerome Teitel, Alexander Keith Stewart, Bernadette Garvey

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A 74-year mild hemophiliac with an inhibitor to factor VIII underwent five 2-L plasma immunoadsorption procedures with a Staphylococcal protein A (Prosorba) column over 7 days. Initially, the inhibitor level increased from 56 to 154 BU/mL. Serum immunoglobulins, immune complexes, C3 and C4 fell progressively with each procedure: C3a was increased. Before therapy, the patient had increased cytotoxic T and activated T cells which decreased to the normal range with treatment. The proportion of T inducer cell and CD4:CD3 ratios increased progressively with each treatment. Natural killer cell activity remained unchanged. Unstimulated patient lymphocytes showed high proliferative activity, but after therapy there was markedly reduced response to mitogens. Both patient and normal lymphocytes showed marked increase in thymidine incorporation when incubated with adsorbed plasma (from column outlet), compared to incubation with unadsorbed plasma (column inlet). The patient's serum showed a progressive rise in this "mitogenicity" effect, maximal after the third procedure, then declining to pre-treatment levels after the fifth procedure. After the third immunoadsorption, inhibitor level was 70 BU/mL and he was given prednisone and cyclophosphamide; after the fifth procedure it was 32 BU/mL and 6 months later was undetectable. Although subsequent decrease in the inhibitor may have been due to the plasma immunoadsorption, it is important to note that this treatment may be paradoxically associated with a rise in antibody levels. In addition to antibody changes, Staph. protein A perfusion affected cellular immunity.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalTransfusion Science
Volume13
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Staphylococcal Protein A
Factor VIII
Therapeutics
Lymphocytes
Antibodies
Helper-Inducer T-Lymphocytes
Prednisone
Antigen-Antibody Complex
Serum
Mitogens
Cellular Immunity
Natural Killer Cells
Cyclophosphamide
Thymidine
Immunoglobulins
Reference Values
Perfusion
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Clinical and immunologic effects of Staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII. / Freedman, John; Semple, John W.; Teitel, Jerome; Stewart, Alexander Keith; Garvey, Bernadette.

In: Transfusion Science, Vol. 13, No. 2, 1992, p. 223-232.

Research output: Contribution to journalArticle

Freedman, John ; Semple, John W. ; Teitel, Jerome ; Stewart, Alexander Keith ; Garvey, Bernadette. / Clinical and immunologic effects of Staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII. In: Transfusion Science. 1992 ; Vol. 13, No. 2. pp. 223-232.
@article{42563c3ec68843f4b75b129d3a21a381,
title = "Clinical and immunologic effects of Staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII",
abstract = "A 74-year mild hemophiliac with an inhibitor to factor VIII underwent five 2-L plasma immunoadsorption procedures with a Staphylococcal protein A (Prosorba) column over 7 days. Initially, the inhibitor level increased from 56 to 154 BU/mL. Serum immunoglobulins, immune complexes, C3 and C4 fell progressively with each procedure: C3a was increased. Before therapy, the patient had increased cytotoxic T and activated T cells which decreased to the normal range with treatment. The proportion of T inducer cell and CD4:CD3 ratios increased progressively with each treatment. Natural killer cell activity remained unchanged. Unstimulated patient lymphocytes showed high proliferative activity, but after therapy there was markedly reduced response to mitogens. Both patient and normal lymphocytes showed marked increase in thymidine incorporation when incubated with adsorbed plasma (from column outlet), compared to incubation with unadsorbed plasma (column inlet). The patient's serum showed a progressive rise in this {"}mitogenicity{"} effect, maximal after the third procedure, then declining to pre-treatment levels after the fifth procedure. After the third immunoadsorption, inhibitor level was 70 BU/mL and he was given prednisone and cyclophosphamide; after the fifth procedure it was 32 BU/mL and 6 months later was undetectable. Although subsequent decrease in the inhibitor may have been due to the plasma immunoadsorption, it is important to note that this treatment may be paradoxically associated with a rise in antibody levels. In addition to antibody changes, Staph. protein A perfusion affected cellular immunity.",
author = "John Freedman and Semple, {John W.} and Jerome Teitel and Stewart, {Alexander Keith} and Bernadette Garvey",
year = "1992",
doi = "10.1016/0955-3886(92)90175-G",
language = "English (US)",
volume = "13",
pages = "223--232",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Clinical and immunologic effects of Staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII

AU - Freedman, John

AU - Semple, John W.

AU - Teitel, Jerome

AU - Stewart, Alexander Keith

AU - Garvey, Bernadette

PY - 1992

Y1 - 1992

N2 - A 74-year mild hemophiliac with an inhibitor to factor VIII underwent five 2-L plasma immunoadsorption procedures with a Staphylococcal protein A (Prosorba) column over 7 days. Initially, the inhibitor level increased from 56 to 154 BU/mL. Serum immunoglobulins, immune complexes, C3 and C4 fell progressively with each procedure: C3a was increased. Before therapy, the patient had increased cytotoxic T and activated T cells which decreased to the normal range with treatment. The proportion of T inducer cell and CD4:CD3 ratios increased progressively with each treatment. Natural killer cell activity remained unchanged. Unstimulated patient lymphocytes showed high proliferative activity, but after therapy there was markedly reduced response to mitogens. Both patient and normal lymphocytes showed marked increase in thymidine incorporation when incubated with adsorbed plasma (from column outlet), compared to incubation with unadsorbed plasma (column inlet). The patient's serum showed a progressive rise in this "mitogenicity" effect, maximal after the third procedure, then declining to pre-treatment levels after the fifth procedure. After the third immunoadsorption, inhibitor level was 70 BU/mL and he was given prednisone and cyclophosphamide; after the fifth procedure it was 32 BU/mL and 6 months later was undetectable. Although subsequent decrease in the inhibitor may have been due to the plasma immunoadsorption, it is important to note that this treatment may be paradoxically associated with a rise in antibody levels. In addition to antibody changes, Staph. protein A perfusion affected cellular immunity.

AB - A 74-year mild hemophiliac with an inhibitor to factor VIII underwent five 2-L plasma immunoadsorption procedures with a Staphylococcal protein A (Prosorba) column over 7 days. Initially, the inhibitor level increased from 56 to 154 BU/mL. Serum immunoglobulins, immune complexes, C3 and C4 fell progressively with each procedure: C3a was increased. Before therapy, the patient had increased cytotoxic T and activated T cells which decreased to the normal range with treatment. The proportion of T inducer cell and CD4:CD3 ratios increased progressively with each treatment. Natural killer cell activity remained unchanged. Unstimulated patient lymphocytes showed high proliferative activity, but after therapy there was markedly reduced response to mitogens. Both patient and normal lymphocytes showed marked increase in thymidine incorporation when incubated with adsorbed plasma (from column outlet), compared to incubation with unadsorbed plasma (column inlet). The patient's serum showed a progressive rise in this "mitogenicity" effect, maximal after the third procedure, then declining to pre-treatment levels after the fifth procedure. After the third immunoadsorption, inhibitor level was 70 BU/mL and he was given prednisone and cyclophosphamide; after the fifth procedure it was 32 BU/mL and 6 months later was undetectable. Although subsequent decrease in the inhibitor may have been due to the plasma immunoadsorption, it is important to note that this treatment may be paradoxically associated with a rise in antibody levels. In addition to antibody changes, Staph. protein A perfusion affected cellular immunity.

UR - http://www.scopus.com/inward/record.url?scp=0026627854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026627854&partnerID=8YFLogxK

U2 - 10.1016/0955-3886(92)90175-G

DO - 10.1016/0955-3886(92)90175-G

M3 - Article

AN - SCOPUS:0026627854

VL - 13

SP - 223

EP - 232

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -